{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:29Z","timestamp":1781196569104,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:00:00Z","timestamp":1574467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:00:00Z","timestamp":1574467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Treatment goals and ambitions have even been upwardly revised since demonstration was made that under certain conditions, treatment-free remission was possible. Herein, we will discuss on how to try tailoring treatment choices to the unique characteristics of each patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Since the first-generation ATP-competitive TKI imatinib was made available in the clinic in 2001, second-generation drugs such as dasatinib, nilotinib and bosutinib and the third-generation TKI ponatinib have broadened the therapeutic armamentarium, providing effective salvage against intolerance and different types of resistance, or as frontline options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Management and outcomes of patients with chronic myeloid leukemia have been revolutionized by the discovery, development, and approval of BCR-ABL tyrosine kinase inhibitors (TKIs). Most patients can now expect a near-to normal life expectancy and acceptable quality of life on life-long treatment, providing awareness and avoidance of harmful adverse events, which depend on each TKI safety profile and patient personal background.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11899-019-00546-4","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T20:03:31Z","timestamp":1580933011000},"page":"492-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"14","author":[{"given":"Florence","family":"Rabian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lengline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,23]]},"reference":[{"issue":"10","key":"546_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood."},{"issue":"5","key":"546_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","journal-title":"Nat Med"},{"issue":"5486","key":"546_CR3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289(5486):1938\u201342.","journal-title":"Science."},{"issue":"23","key":"546_CR4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"546_CR5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"19","key":"546_CR6","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"\u2022\u2022 Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758\u201365 Study highlighted prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia.","journal-title":"Blood."},{"issue":"4","key":"546_CR7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"19","key":"546_CR8","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim D-W, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204\u201312.","journal-title":"J Clin Oncol"},{"issue":"10","key":"546_CR9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136.","journal-title":"Blood."},{"issue":"15","key":"546_CR10","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim D-W, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119(15):3403\u201312.","journal-title":"Blood."},{"issue":"5","key":"546_CR11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312.","journal-title":"Cancer Cell"},{"issue":"19","key":"546_CR12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"24","key":"546_CR13","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"24","key":"546_CR14","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"546_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"\u2022\u2022 Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137 Comparaison of efficiency and safety of second generation TKI bosutinib vs imainib.","journal-title":"J Clin Oncol"},{"issue":"5","key":"546_CR16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"Jeffrey H Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u201321.","journal-title":"The Lancet Oncology"},{"issue":"4","key":"546_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12185-017-2295-0","volume":"108","author":"D Rea","year":"2018","unstructured":"Rea D, Cayuela J-M. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;108(4):355\u201364.","journal-title":"Int J Hematol"},{"issue":"20","key":"546_CR18","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"\u2022\u2022 Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333\u201340 Comparaison of efficiency and safety of second generation TKI dasatinib vs imainib.","journal-title":"J Clin Oncol"},{"issue":"6","key":"546_CR19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood."},{"issue":"9","key":"546_CR20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1108\u201335.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"546_CR21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"\u2022\u2022 Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354 Comparison of efficiency and safety of second generation TKI nilotinib vs imainib.","journal-title":"Leukemia."},{"issue":"12","key":"546_CR22","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","volume":"94","author":"A Fabarius","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015;94(12):2015\u201324.","journal-title":"Ann Hematol"},{"key":"546_CR23","unstructured":"Pubmeddev, SJ et al.. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. - PubMed - NCBI [Internet]. [cit\u00e9 20 ao\u00fbt 2019]."},{"issue":"Suppl 2","key":"546_CR24","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1007\/s00277-015-2318-y","volume":"94","author":"D Rea","year":"2015","unstructured":"Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015;94(Suppl 2):S149\u201358.","journal-title":"Ann Hematol"},{"issue":"21","key":"546_CR25","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121(21):3894\u2013904.","journal-title":"Cancer."},{"issue":"3","key":"546_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clml.2015.12.001","volume":"16","author":"E Vidal-Petiot","year":"2016","unstructured":"Vidal-Petiot E, Rea D, Serrano F, Stehl\u00e9 T, Gardin C, Rousselot P, et al. Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):169\u201374.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"546_CR27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner G-H, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125(6):901\u20136.","journal-title":"Blood."},{"issue":"5","key":"546_CR28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/leu.2014.342","volume":"29","author":"D Rea","year":"2015","unstructured":"Rea D, Mirault T, Raffoux E, Boissel N, Andreoli AL, Rousselot P, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29(5):1206\u20139.","journal-title":"Leukemia"},{"issue":"7","key":"546_CR29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","volume":"99","author":"D Rea","year":"2014","unstructured":"Rea D, Mirault T, Cluzeau T, Gautier J-F, Guilhot F, Dombret H, et al. Early onset hypercholesterolemia induced by the second-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99(7):1197\u2013203.","journal-title":"Haematologica"},{"issue":"10","key":"546_CR30","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1002\/ajh.25232","volume":"93","author":"Z Racil","year":"2018","unstructured":"Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, et al. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Am J Hematol. 2018;93(10):E342\u20135.","journal-title":"Am J Hematol"},{"issue":"1","key":"546_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","volume":"104","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104(1):93\u2013101.","journal-title":"Haematologica"},{"issue":"11","key":"546_CR32","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","volume":"90","author":"NP Shah","year":"2015","unstructured":"Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060\u20134.","journal-title":"Am J Hematol"},{"issue":"9","key":"546_CR33","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","volume":"114","author":"M-P Gratacap","year":"2009","unstructured":"Gratacap M-P, Martin V, Val\u00e9ra M-C, Allart S, Garcia C, Si\u00e9 P, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114(9):1884\u201392.","journal-title":"Blood."},{"issue":"19","key":"546_CR34","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1182\/blood-2010-12-326850","volume":"117","author":"A Mazharian","year":"2011","unstructured":"Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood. 2011;117(19):5198\u2013206.","journal-title":"Blood."},{"issue":"3","key":"546_CR35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346\u201357.","journal-title":"Am J Hematol"},{"issue":"12","key":"546_CR36","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123\u20137.","journal-title":"Cancer."},{"issue":"2","key":"546_CR37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bulcan.2015.11.008","volume":"103","author":"D Rea","year":"2016","unstructured":"Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, et al. Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Bull Cancer. 2016;103(2):180\u20139.","journal-title":"Bull Cancer"},{"issue":"Suppl 2","key":"546_CR38","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","volume":"94","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, Hochhaus A, M\u00fcller MC. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol. 2015;94(Suppl 2):S219\u201325.","journal-title":"Ann Hematol"},{"issue":"1","key":"546_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17\u201323.","journal-title":"Blood."},{"issue":"14","key":"546_CR40","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","volume":"124","author":"D Rea","year":"2018","unstructured":"Rea D, Ame S, Berger M, Cayuela J-M, Charbonnier A, Coiteux V, et al. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer. 2018;124(14):2956\u201363.","journal-title":"Cancer."},{"issue":"9","key":"546_CR41","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","volume":"97","author":"M Breccia","year":"2018","unstructured":"Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sor\u00e0 F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018;97(9):1577\u201380.","journal-title":"Ann Hematol"},{"issue":"1","key":"546_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","volume":"39","author":"JH Lipton","year":"2015","unstructured":"Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S, et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39(1):58\u201364.","journal-title":"Leuk Res"},{"issue":"25","key":"546_CR43","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, M\u00fcller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27(25):4204\u201310.","journal-title":"J Clin Oncol"},{"issue":"24","key":"546_CR44","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944\u201353.","journal-title":"Blood."},{"issue":"8","key":"546_CR45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"Carlo Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim D-W, Schafhausen P, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103(8):1298\u2013307.","journal-title":"Haematologica"},{"issue":"4","key":"546_CR46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404.","journal-title":"Blood."},{"issue":"15","key":"546_CR47","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim D-W, Olavarria E, Pinilla-Ibarz J, Apperley JF, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123(15):2875\u201380.","journal-title":"Cancer."},{"issue":"19","key":"546_CR48","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818\u201324.","journal-title":"Blood."},{"issue":"6","key":"546_CR49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.31187","volume":"124","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Kantarjian H, O\u2019Brien S, Ravandi F, Konopleva M, Borthakur G, et al. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018;124(6):1160\u20138.","journal-title":"Cancer."},{"issue":"11","key":"546_CR50","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/leu.2017.247","volume":"31","author":"TP Hughes","year":"2017","unstructured":"\u2022 Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31(11):2529\u201331.","journal-title":"Leukemia."},{"issue":"6","key":"546_CR51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015;125(6):915\u201323.","journal-title":"Blood."},{"issue":"6","key":"546_CR52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2016.03.004","volume":"16","author":"HJ Khoury","year":"2016","unstructured":"Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, et al. Cross- intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(6):341\u2013349.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"546_CR53","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","volume":"117","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011;117(21):5600\u20136.","journal-title":"Blood."},{"key":"546_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2018.02.013","volume":"67","author":"D Hiwase","year":"2018","unstructured":"Hiwase D, Tan P, D\u2019Rozario J, Taper J, Powell A, Irving I, et al. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leuk Res. 2018;67:109\u201315.","journal-title":"Leuk Res"},{"issue":"5","key":"546_CR55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, et al. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk. 2016;16(5):286\u201396.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"546_CR56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"Jorge E. Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim D-W, Schafhausen P, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91(12):1206\u201314.","journal-title":"American Journal of Hematology"},{"issue":"8","key":"546_CR57","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835\u201350.","journal-title":"Leukemia"},{"issue":"7","key":"546_CR58","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375\u201383.","journal-title":"Lancet Haematol"},{"key":"546_CR59","unstructured":"Rea D, Cayuela J-M, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood. 2017;130(Suppl 1):318\u20138."},{"issue":"13","key":"546_CR60","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","volume":"124","author":"K Naqvi","year":"2018","unstructured":"Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, et al. Early results of lower dose dasatinib (50\u2009mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018;124(13):2740\u20137.","journal-title":"Cancer."},{"issue":"7647","key":"546_CR61","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00546-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:49:46Z","timestamp":1695718186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00546-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,23]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00546-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,23]]},"assertion":[{"value":"23 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Rea reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, and personal fees from Incyte during the conduct of the study. Dr. Rabian and Dr. Lengline have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}